Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study.

Roex MCJ, van Balen P, Germeroth L, Hageman L, van Egmond E, Veld SAJ, Hoogstraten C, van Liempt E, Zwaginga JJ, de Wreede LC, Meij P, Vossen ACTM, Danhof S, Einsele H, Schaafsma MR, Veelken H, Halkes CJM, Jedema I, Falkenburg JHF.

Leukemia. 2019 Oct 17. doi: 10.1038/s41375-019-0600-z. [Epub ahead of print]

PMID:
31624377
2.

Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial.

Minnema MC, Nasserinejad K, Hazenberg B, Hegenbart U, Vlummens P, Ypma PF, Kröger N, Wu KL, Kersten MJ, Schaafsma MR, Croockewit S, de Waal E, Zweegman S, Tick L, Broijl A, Koene H, Bos G, Sonneveld P, Schönland S.

Haematologica. 2019 Nov;104(11):2274-2282. doi: 10.3324/haematol.2018.213900. Epub 2019 Mar 28.

3.

Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.

Kater AP, van Oers MHJ, van Norden Y, van der Straten L, Driessen J, Posthuma WFM, Schipperus M, Chamuleau MED, Nijland M, Doorduijn JK, Van Gelder M, Hoogendoorn M, De Croon F, Wittebol S, Kerst JM, Marijt EWA, Raymakers RAP, Schaafsma MR, Dobber JA, Kersting S, Levin MD; HOVON CLL study group.

Haematologica. 2019 Jan;104(1):147-154. doi: 10.3324/haematol.2018.193854. Epub 2018 Aug 16.

4.

Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial.

Stevens-Kroef MJ, Olde Weghuis D, ElIdrissi-Zaynoun N, van der Reijden B, Cremers EMP, Alhan C, Westers TM, Visser-Wisselaar HA, Chitu DA, Cunha SM, Vellenga E, Klein SK, Wijermans P, de Greef GE, Schaafsma MR, Muus P, Ossenkoppele GJ, van de Loosdrecht AA, Jansen JH.

Genes Chromosomes Cancer. 2017 Jul;56(7):524-534. doi: 10.1002/gcc.22455. Epub 2017 Mar 31.

PMID:
28236351
5.

Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.

Doorduijn JK, van Imhoff GW, van der Holt B, Schouten HC, Schaafsma MR, MacKenzie MA, Baars JW, Kersten MJ, Lugtenburg PJ, van den Bent MJ, Enting RH, Spoelstra FM, Poortmans P, Bromberg JEC.

Hematol Oncol. 2017 Dec;35(4):497-503. doi: 10.1002/hon.2342. Epub 2016 Aug 17.

PMID:
27530779
6.

Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study.

Holtzer-Goor KM, Schaafsma MR, Joosten P, Posthuma EF, Wittebol S, Huijgens PC, Mattijssen EJ, Vreugdenhil G, Visser H, Peters WG, Erjavec Z, Wijermans PW, Daenen SM, van der Hem KG, van Oers MH, Uyl-de Groot CA.

Qual Life Res. 2015 Dec;24(12):2895-906. doi: 10.1007/s11136-015-1039-y. Epub 2015 Jul 24.

7.

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years.

Cornelissen JJ, Versluis J, Passweg JR, van Putten WL, Manz MG, Maertens J, Beverloo HB, Valk PJ, van Marwijk Kooy M, Wijermans PW, Schaafsma MR, Biemond BJ, Vekemans MC, Breems DA, Verdonck LF, Fey MF, Jongen-Lavrencic M, Janssen JJ, Huls G, Kuball J, Pabst T, Graux C, Schouten HC, Gratwohl A, Vellenga E, Ossenkoppele G, Löwenberg B; HOVON; SAKK Leukemia Groups.

Leukemia. 2015 May;29(5):1041-50. doi: 10.1038/leu.2014.332. Epub 2014 Nov 27.

PMID:
25428261
8.

Hepatocellular carcinoma after danazol treatment for hereditary angio-oedema.

Berkel AE, Bouman DE, Schaafsma MR, Verhoef C, Klaase JM.

Neth J Med. 2014 Sep;72(7):380-2.

9.

Real-world costs of chronic lymphocytic leukaemia in the Netherlands.

Holtzer-Goor KM, Bouwmans-Frijters CA, Schaafsma MR, de Weerdt O, Joosten P, Posthuma EF, Wittebol S, Huijgens PC, Mattijssen EJ, Vreugdenhil G, Visser H, Peters WG, Erjavec Z, Wijermans PW, Daenen SM, van der Hem KG, van Oers MH, Groot CA.

Leuk Res. 2014 Jan;38(1):84-90. doi: 10.1016/j.leukres.2013.10.029. Epub 2013 Nov 8.

PMID:
24268350
10.

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Hänel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM.

Haematologica. 2014 Jan;99(1):148-54. doi: 10.3324/haematol.2013.087585. Epub 2013 Aug 30.

11.

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM.

J Clin Oncol. 2012 Aug 20;30(24):2946-55. doi: 10.1200/JCO.2011.39.6820. Epub 2012 Jul 16. Erratum in: J Clin Oncol. 2012 Oct 10;30(29):3654.

PMID:
22802322
12.

Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.

Verelst SG, Termorshuizen F, Uyl-de Groot CA, Schaafsma MR, Ammerlaan AH, Wittebol S, Sinnige HA, Zweegman S, van Marwijk Kooy M, van der Griend R, Lokhorst HM, Sonneveld P, Wijermans PW; Dutch-Belgium Hemato-Oncology Cooperative Group (HOVON).

Ann Hematol. 2011 Dec;90(12):1427-39. doi: 10.1007/s00277-011-1224-1. Epub 2011 Apr 7.

PMID:
21472373
13.

Cytarabine dose for acute myeloid leukemia.

Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group.

N Engl J Med. 2011 Mar 17;364(11):1027-36. doi: 10.1056/NEJMoa1010222.

14.

Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.

Kneppers E, Lokhorst HM, Eeltink CM, Huls G, Kersten MJ, Koedam J, Minnema MC, van Oers MH, Raymakers RA, Schaafsma MR, Vellenga E, Wijermans PW, Wittebol S, Sonneveld P, Zweegman S.

Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):138-43. doi: 10.3816/CLML.2010.n.020.

PMID:
20371448
15.

Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison.

Cornelissen JJ, van der Holt B, Verhoef GE, van't Veer MB, van Oers MH, Schouten HC, Ossenkoppele G, Sonneveld P, Maertens J, van Marwijk Kooy M, Schaafsma MR, Wijermans PW, Biesma DH, Wittebol S, Voogt PJ, Baars JW, Zachée P, Verdonck LF, Löwenberg B, Dekker AW; Dutch-Belgian HOVON Cooperative Group.

Blood. 2009 Feb 5;113(6):1375-82. doi: 10.1182/blood-2008-07-168625. Epub 2008 Nov 6.

PMID:
18988865
16.

Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial.

Sonneveld P, van der Holt B, Segeren CM, Vellenga E, Croockewit AJ, Verhoe GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Westveer PH, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).

Haematologica. 2007 Jul;92(7):928-35.

17.

Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene.

van Bergen CA, Kester MG, Jedema I, Heemskerk MH, van Luxemburg-Heijs SA, Kloosterboer FM, Marijt WA, de Ru AH, Schaafsma MR, Willemze R, van Veelen PA, Falkenburg JH.

Blood. 2007 May 1;109(9):4089-96. Epub 2007 Jan 18.

PMID:
17234742
18.

Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer.

Slager EH, Honders MW, van der Meijden ED, van Luxemburg-Heijs SA, Kloosterboer FM, Kester MG, Jedema I, Marijt WA, Schaafsma MR, Willemze R, Falkenburg JH.

Blood. 2006 Jun 15;107(12):4954-60. Epub 2006 Feb 23.

PMID:
16497972
19.

Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma.

van Agthoven M, Kramer MH, Sonneveld P, van der Hem KG, Huijgens PC, Wijermans PW, Kluin-Nelemans HC, Schaafsma MR, Biesma DH, Mattijssen V, Uyl-de Groot CA, Hagenbeek A.

Haematologica. 2005 Oct;90(10):1422-32.

20.

Primary allogeneic T-cell responses against mantle cell lymphoma antigen-presenting cells for adoptive immunotherapy after stem cell transplantation.

Hoogendoorn M, Olde Wolbers J, Smit WM, Schaafsma MR, Jedema I, Barge RM, Willemze R, Falkenburg JH.

Clin Cancer Res. 2005 Jul 15;11(14):5310-8.

21.

Economic assessment on the management of chronic lymphocytic leukaemia.

Goor KM, Schaafsma MR, Huijgens PC, van Agthoven M.

Expert Opin Pharmacother. 2005 Jun;6(7):1179-89. Review.

PMID:
15957971
22.
23.

The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.

Ossenkoppele GJ, Graveland WJ, Sonneveld P, Daenen SM, Biesma DH, Verdonck LF, Schaafsma MR, Westveer PH, Peters GJ, Noordhuis P, Muus P, Selleslag D, van der Holt B, Delforge M, Löwenberg B, Verhoef GE; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).

Blood. 2004 Apr 15;103(8):2908-13. Epub 2003 Dec 4. Erratum in: Blood. 2004 Jul 1;104(1):42.

PMID:
15070662
24.

CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.

Doorduijn JK, van der Holt B, van Imhoff GW, van der Hem KG, Kramer MH, van Oers MH, Ossenkoppele GJ, Schaafsma MR, Verdonck LF, Verhoef GE, Steijaert MM, Buijt I, Uyl-de Groot CA, van Agthoven M, Mulder AH, Sonneveld P.

J Clin Oncol. 2003 Aug 15;21(16):3041-50.

PMID:
12915593
25.

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.

Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Fibbe WE, Wittebol S, Schouten HC, van Marwijk Kooy M, Biesma DH, Baars JW, Slater R, Steijaert MM, Buijt I, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Study Group.

Blood. 2003 Mar 15;101(6):2144-51. Epub 2002 Nov 27.

PMID:
12456509
26.

[Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].

Wu KL, Schaafsma MR, Lokhorst HM, Wijermans PW, van der Holt B, Sonneveld P.

Ned Tijdschr Geneeskd. 2002 Aug 3;146(31):1445-8. Dutch.

PMID:
12190011
27.

Highly purified CD34+ cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients.

Richel DJ, Johnsen HE, Canon J, Guillaume T, Schaafsma MR, Schenkeveld C, Hansen SW, McNiece I, Gringeri AJ, Briddell R, Ewen C, Davies R, Freeman J, Miltenyi S, Symann M.

Bone Marrow Transplant. 2000 Feb;25(3):243-9.

28.

Vulvar paraneoplastic amyloidosis with the appearance of a vulvar carcinoma.

Persoons JH, Sutorius FJ, Koopman RJ, Schaafsma MR, van Doorn GA.

Am J Obstet Gynecol. 1999 Apr;180(4):1041-4.

PMID:
10203681
29.

Photosensitive seizures associated with interferon alfa-2a.

Brouwers PJ, Bosker RJ, Schaafsma MR, Wilts G, Neef C.

Ann Pharmacother. 1999 Jan;33(1):113-4. No abstract available.

PMID:
9972396
30.

Ex vivo evidence of lymphocyte apoptosis in hairy cell leukemia, induced by 2-chlorodeoxyadenosine treatment.

Idink-Mecking CA, Richel DJ, Vermes I, Schaafsma MR, Reutelingsperger C, Haanen C.

Ann Hematol. 1998 Jan;76(1):25-9.

PMID:
9486921
31.

Apoptosis and secondary necrosis of lymphocytes in culture.

Vermes I, Haanen C, Richel DJ, Schaafsma MR, Kalsbeek-Batenburg E, Reutelingsperger CP.

Acta Haematol. 1997;98(1):8-13.

PMID:
9210907
32.

Clinical and toxicological aspects of the antineoplastic drug cladribine: a review.

Guchelaar HJ, Richel DJ, Schaafsma MR.

Ann Hematol. 1994 Nov;69(5):223-30. Review.

PMID:
7948311
33.

Lactic acidosis in a patient with B-cell non-Hodgkin's lymphoma.

Scheurleer-Hommes ML, Schaafsma MR, Kluin-Nelemans JC.

Leukemia. 1994 Jun;8(6):1065-6.

PMID:
8207979
34.

Interleukin-9 stimulates the proliferation of enriched human erythroid progenitor cells: additive effect with GM-CSF.

Schaafsma MR, Falkenburg JH, Duinkerken N, Van Snick J, Landegent JE, Willemze R, Fibbe WE.

Ann Hematol. 1993 Jan;66(1):45-9.

PMID:
8431521
35.

Human interleukin for DA cells (HILDA) does not affect the proliferation and differentiation of hematopoietic progenitor cells in human long-term bone marrow cultures.

Schaafsma MR, Falkenburg JH, Duinkerken N, Moreau JF, Soulillou JP, Willemze R, Fibbe WE.

Exp Hematol. 1992 Jan;20(1):6-10.

PMID:
1577095
36.

In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophages colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients.

Schaafsma MR, Falkenburg JH, Landegent JE, Duinkerken N, Osanto S, Ralph P, Kaushansky K, Wagemaker G, Van Damme J, Willemze R, et al.

Blood. 1991 Oct 15;78(8):1981-7.

PMID:
1912580
37.

Increased numbers of circulating haematopoietic progenitor cells after treatment with high-dose interleukin-2 in cancer patients.

Schaafsma MR, Fibbe WE, van der Harst D, Duinkerken N, Brand A, Osanto S, Franks CR, Willemze R, Falkenburg JH.

Br J Haematol. 1990 Oct;76(2):180-5.

PMID:
2094321
38.

Interleukin-6 is not involved in the interleukin-1-induced production of colony-stimulating factors by human bone marrow stromal cells and fibroblasts.

Schaafsma MR, Fibbe WE, Van Damme J, Duinkerken N, Ralph P, Kaushansky K, Altrock BW, Willemze R, Falkenburg JH.

Blood. 1989 Dec;74(8):2619-23.

PMID:
2479424
39.

Interleukin-1 synergizes with granulocyte-macrophage colony-stimulating factor on granulocytic colony formation by intermediate production of granulocyte colony-stimulating factor.

Schaafsma MR, Falkenburg JH, Duinkerken N, Van Damme J, Altrock BW, Willemze R, Fibbe WE.

Blood. 1989 Nov 15;74(7):2398-404.

PMID:
2478229
40.

The biological activities of interleukin-1.

Fibbe WE, Schaafsma MR, Falkenburg JH, Willemze R.

Blut. 1989 Aug;59(2):147-56. Review.

PMID:
2527574
41.

The hematopoietic activities of interleukin-1.

Fibbe WE, Falkenburg JH, Schaafsma MR, Willemze R.

Biotherapy. 1989;1(4):263-71. Review. No abstract available.

PMID:
2701642
42.

Interleukin 1 induces different cytokines in human fibroblasts.

Van Damme J, Schaafsma MR, Conings R, Lenaerts JP, Put W, Billiau A, Fibbe WE.

Lymphokine Res. 1989 Fall;8(3):289-92. No abstract available.

PMID:
2674556
43.

Simultaneous production of interleukin 6, interferon-beta and colony-stimulating activity by fibroblasts after viral and bacterial infection.

Van Damme J, Schaafsma MR, Fibbe WE, Falkenburg JH, Opdenakker G, Billiau A.

Eur J Immunol. 1989 Jan;19(1):163-8.

PMID:
2646135
44.

Gall bladder perforation in response to chemotherapy in a patient with a histiocytic lymphoma.

Schaafsma MR, Peters WG, Tham RT, Alleman MJ, Willemze R.

Neth J Med. 1988 Aug;33(1-2):78-82. No abstract available.

PMID:
2469970
45.

Staging and treatment of non-Hodgkin's lymphoma of intermediate-grade malignancy: a retrospective study of 102 cases.

Schaafsma MR, Bieger R, Hermans J, Kluin PM, Noordijk EM, Willemze ER.

Eur J Haematol. 1987 Sep;39(3):252-8.

PMID:
3678476
46.

Agranulocytosis induced by propylthiouracil: evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cells.

Fibbe WE, Claas FH, Van der Star-Dijkstra W, Schaafsma MR, Meyboom RH, Falkenburg JH.

Br J Haematol. 1986 Oct;64(2):363-73.

PMID:
3778829
47.

Recovery of hematopoiesis after blood-group-incompatible bone marrow transplantation with red-blood-cell-depleted grafts.

Falkenburg JH, Schaafsma MR, Jansen J, Brand A, Goselink HM, Zwaan FE, Eernisse JG.

Transplantation. 1985 May;39(5):514-20.

PMID:
3887691
48.

Removal of red cells in ABO-incompatible bone marrow transplantation.

Schaafsma MR, Falkenburg JH, Eernisse JG.

Lancet. 1983 Jan 1;1(8314-5):67. No abstract available.

PMID:
6129396

Supplemental Content

Loading ...
Support Center